Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of CS-7017 in Japanese Patients With Solid Cancer
jRCT2080220936Phase 1
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of efatutazone in Non-hematologic malignancy, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Safety and tolerability of efatutazone (CS-7017) and Pharmacokinetics of efatutazone (CS-7017).
02
Drugs
efatutazone
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2080220936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220936.